Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Fulcrum Therapeutics in a note issued to investors on Monday, May 20th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($0.78) per share for the year. Cantor Fitzgerald currently has a […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors bought 9,544 call options on the company. This represents an increase of approximately 867% compared to the typical volume of 987 call options. Fulcrum Therapeutics Stock Down 0.8 % FULC stock opened at $7.64 on […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders bought 9,544 call options on the stock. This represents an increase of 867% compared to the average daily volume of 987 call options. Insider Buying and Selling In other Fulcrum Therapeutics news, VP Greg Tourangeau […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Leerink Partnrs upped their Q2 2024 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report released on Monday, May 13th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of $0.74 for the quarter, up from their […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Research analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.43) per share for the quarter, down from […]